



Washington State Health Care Authority  
**Prescription Drug Program**

626 8<sup>th</sup> Ave SE, Olympia, WA 98501

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

October 31, 2024

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective December 1, 2024:

MS Drugs reviewed 4/17/2024		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dimethyl fumarate	dimethyl fumarate capsule	Not participating	Yes
	dimethyl fumarate starterpack		Yes
diroximel fumarate	Vumerity <sup>®</sup> capsule		Yes
fingolimod HCL	Gilenya <sup>®</sup> capsule		Yes
glatiramer acetate	glatiramer acetate syringe		Yes
	Glatopa <sup>®</sup> syringe		Yes
interferon beta-1A	Avonex <sup>®</sup> kit		Yes
	Avonex Pen <sup>®</sup> kit		Yes
	Rebif <sup>®</sup> syringe		Yes
	Rebif Rebidose <sup>®</sup> auto-inject		Yes
	Rebif Rebidose Titration Pack <sup>®</sup> auto-inject	Yes	
	Rebif Titration Pack <sup>®</sup> syringe	Yes	
ofatumumab	Kesimpta <sup>®</sup> auto-inject	Yes	
teriflunomide	Aubagio <sup>®</sup> tablet	Yes	

The effect of this recommendation is to make Kesimpta<sup>®</sup> and Rebif<sup>®</sup> preferred on the WA PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at [leta.evaskus@hca.wa.gov](mailto:leta.evaskus@hca.wa.gov).

Sincerely,

Donna Sullivan  
Chief Pharmacy Officer  
Clinical Quality and Care Transformation  
Washington State Health Care Authority